Cytokinetics, Olympic Medalist McLaughlin-Levrone team up for awareness for HCM
Cytokinetics (CYTK), Incorporated announced the launch of “On Track with HCM,” demonstrating the company’s long-standing commitment to the, Hypertrophic Cardiomyopathy, HCM community. The campaign features four-time Olympic gold medalist Sydney McLaughlin-Levrone, and her father, three-time all-American track star, Willie McLaughlin, who suffered from the non-obstructive form of hypertrophic cardiomyopathy, HCM, for more than two decades before receiving a heart transplant.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
Disclaimer & DisclosureReport an Issue
- Cytokinetics announces Myqorzo available in U.S.
- Cytokinetics price target raised to $108 from $90 at B. Riley
- 3 ‘Strong Buy’ Stocks to Buy Today, 1/14/2026, According to Top Analysts
- Cytokinetics price target raised to $90 from $71 at Morgan Stanley
- Tango Therapeutics appoints Sung Lee to board of directors
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.